Entities / Company
Curis (United States).
company in Lexington, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 19
What's happening
Gone quiet
No new reports in 90+ days-
Genentech is a member of the Roche Group, and Genentech commercializes Erivedge which is licensed from Curis.Some support2 reports
-
Curis filed a registration statement with the Securities and Exchange Commission (Bangladesh) on July 2, 2025, with Jones acting as the placement agent.Speculative1 report
-
Curis shares dropped 47.7% on August 5, 2025, while the S&P 500 gained 7.6%.Some support1 report
-
Curis is seeking regulatory approval for its drug candidate emavusertib, having received Orphan Drug Designations from both the FDA and EMA.Some support1 report
-
Curis is seeking accelerated submissions in Europe for its work on BTK inhibitors, specifically regarding the Taga lymphoma study.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Curis (United States) this week
News at the entities that move Curis (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Curis (United States)
Connections
The 1 strongest of 19, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Curis seeks regulatory approval and registration from the FDA for its products.
History
Events by the month they beganJune 2026
5 events- Genentech is a member of the Roche Group, and Genentech commercializes Erivedge which is licensed from Curis.
- Curis filed a registration statement with the Securities and Exchange Commission (Bangladesh) on July 2, 2025, with Jones acting as the placement agent.
- Curis shares dropped 47.7% on August 5, 2025, while the S&P 500 gained 7.6%.
- Curis is seeking regulatory approval for its drug candidate emavusertib, having received Orphan Drug Designations from both the FDA and EMA.
- Curis is seeking accelerated submissions in Europe for its work on BTK inhibitors, specifically regarding the Taga lymphoma study.